Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

A New Discovery in Early Cancer Diagnosis – Synthetic Biopsy

A New Discovery in Early Cancer Diagnosis – Synthetic Biopsy

Stanford University has announced a new platform based on synthetic biopsy technology, designed to detect the location of cancer early.

Earli markers – completely different from the others

The biotechnology industry is pursuing major technological breakthroughs promising early cancer diagnosis, because survival rates are substantially higher. Earli, a bioengineering company developing a new technology platform that allows doctors to locate cancer precisely and early so it can be treated, announced on 12 January 2021 that it had received 40 million dollars in funding.

“What we promise is for every person affected by cancer and their families. By locating cancer early, the disease can be treated; we can and will change the statistics.”

Using technology licensed from Stanford University, Earli is creating a new platform that uses a genetic construct to force cancer to produce biomarkers not normally expressed in the human body, called synthetic biopsy. Early localization of cancer through synthetic biopsy allows more precise treatments.

“The Earli platform is fundamentally different from other early cancer detection methods and treatment approaches. We believe Earli has the potential to change the book on cancer forever,” says Khosla Ventures founder Vinod Khosla.

Justin Kao, the partner at Khosla Venterus who will also join Earli's board, adds “2020 proved that biotechnology can deliver incredible innovation and discovery within a compressed timeframe. Earli reached the clinical trial stage within two and a half years of its inception – a remarkable period considering the depth of the project, the challenges of Covid-19 and the potential impact the company could have in the fight against cancer.”

Cyriac Roeding, Earli's co-founder and CEO, said “Funding from some of the world's leading biotechnology investors comes at exactly the right time as Earli begins human clinical trials and moves towards commercialization to help patients”.

How does Earli's early diagnosis system work?

Stanford University uses synthetic biopsy as an unconventional approach. Rather than relying on biomarkers that cancer may or may not naturally shed, a synthetic compound is injected that disperses throughout the body, randomly entering healthy cells and also cancer cells if present. If the prepared synthetic biopsy material enters a cancer cell, it forces the cell to reveal itself, making detection easier.

Dr. David Suhy, Earli's co-founder, said “Two types of biopsy are accepted for cancer detection: traditional tissue biopsy and liquid/fluid biopsies. Liquid biopsies use chemistry to investigate naturally shed biomarkers through sequencing and methylation patterns in cell-free circulating tumour DNA, detection of protein biomarkers or the presence of circulating tumour cells. As the tumour gets smaller, detecting cancer with this conventional liquid biopsy method becomes increasingly difficult, and if tumours are detected, they may be too small to image and locate precisely, or conventional imaging cannot determine whether a tumour is benign or malignant”.

Earli synthetic biopsy new method for early cancer diagnosis PET scan

The Earli platform was designed to solve this problem. Rather than chemistry, it uses biology to produce a series of cancer-activated synthetic biomarkers designed to locate a malignant tumour precisely in a particular tissue.

Earli clinical study data

Recent key studies have shown that Earli's detection technology can scale from mice carrying artificially induced cancer to dogs with naturally occurring spontaneous cancer. These results are important because the dog study design closely resembles the first human clinical trials, the next step for Earli in 2021.  

Today, 70% of all cancers are detected at an advanced stage, namely stage 3 or 4. By the time cancer symptoms appear, it is often too late. The 5-year survival rate for stage 4 cancers is between 25-50%. Earli's mission is to find evidence of cancer in phase 1 or phase 2 and locate it for precision treatment, which would mean helping more than a million lives annually.

Sources

Earli Raises $40 Million Series A Funding Led by Khosla Ventures, With Perceptive Advisors, Casdin Capital, Andreessen Horowitz, Sands Capital. (2021, Jan 12). businesswire a berkshire hathaway compayny: retrieved from www.businesswire.com

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

A New Discovery in Early Cancer Diagnosis – Synthetic Biopsy

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy